ACADIA Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $250,401 | $241,963 | $205,831 | $231,041 |
Gross Profit | 231,544 | 223,733 | 182,880 | 213,150 |
EBITDA | 31,644 | 33,008 | 20,738 | 36,581 |
EBIT | 30,437 | 15,210 | 34,944 | |
Net Income | 32,765 | 33,389 | 16,555 | 45,797 |
Net Change In Cash | 250,401 | 241,963 | 205,831 | 231,041 |
Free Cash Flow | 63,176 | 25,013 | 29,079 | 85,389 |
Cash | 155,149 | 177,134 | 204,745 | 188,657 |
Basic Shares | 166,178 | 166,174 | 166,623 | 166,510 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $726,437 | $517,235 | $484,145 | $441,755 |
Gross Profit | 680,706 | 507,069 | 465,004 | 421,205 |
EBITDA | -67,827 | -221,570 | -167,095 | -283,654 |
EBIT | -73,379 | -223,596 | -170,439 | -286,586 |
Net Income | -61,286 | -215,975 | -167,870 | -281,584 |
Net Change In Cash | 726,437 | 517,235 | 484,145 | 441,755 |
Cost of Revenue | -178,600 | 137,339 | ||
Free Cash Flow | -23,348 | -114,035 | -126,782 | -143,753 |
Cash | 188,657 | 114,846 | 147,435 | 326,028 |
Basic Shares | 163,819 | 161,683 | 160,493 | 157,331 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.20 |
2024-06-30 | $0.20 |
2024-03-31 | $0.10 |
2023-12-31 | $0.28 |
